Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Equity Ratio (2016 - 2025)

Seres Therapeutics' Equity Ratio history spans 11 years, with the latest figure at 0.3 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 127.6% year-over-year to 0.3; the TTM value through Sep 2025 reached 0.3, up 127.6%, while the annual FY2024 figure was 0.1, 178.82% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.3 at Seres Therapeutics, up from 0.23 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.47 in Q1 2021 and bottomed at 0.27 in Q2 2024.
  • The 5-year median for Equity Ratio is 0.13 (2024), against an average of 0.14.
  • The largest YoY upside for Equity Ratio was 425.37% in 2024 against a maximum downside of 586.36% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.37 in 2021, then crashed by 91.66% to 0.03 in 2022, then plummeted by 504.6% to 0.13 in 2023, then skyrocketed by 178.82% to 0.1 in 2024, then skyrocketed by 208.92% to 0.3 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Equity Ratio are 0.3 (Q3 2025), 0.23 (Q2 2025), and 0.31 (Q1 2025).